Difference between revisions of "Reversible inhibition of sperm under guidance"
Jump to navigation
Jump to search
(Created page with "Category: Male Contraceptives") |
|||
| Line 1: | Line 1: | ||
| + | [[Reversible inhibition of sperm under guidance]] (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive injection developed at IIT Kharagpur in India by the team of Dr. Sujoy K. Guha.[citation needed] |
||
| + | |||
| + | RISUG has been patented in India, China, Bangladesh, and the United States.[1] Phase III clinical trials were underway in India, and were slowed by insufficient volunteers.[1] |
||
| + | |||
| + | Beginning in 2011, a contraceptive product based on RISUG, Vasalgel, was under development in the US by Parsemus Foundation.[2] In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to bring the technology to market under the name Plan A for Men.[3] |
||
| + | |||
[[Category: Male Contraceptives]] |
[[Category: Male Contraceptives]] |
||
Revision as of 02:19, 18 January 2024
Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive injection developed at IIT Kharagpur in India by the team of Dr. Sujoy K. Guha.[citation needed]
RISUG has been patented in India, China, Bangladesh, and the United States.[1] Phase III clinical trials were underway in India, and were slowed by insufficient volunteers.[1]
Beginning in 2011, a contraceptive product based on RISUG, Vasalgel, was under development in the US by Parsemus Foundation.[2] In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to bring the technology to market under the name Plan A for Men.[3]